CN104311498B - Triazole sulphonyl propanedioic acid compounds, Preparation Method And The Use that alkoxyl group replaces - Google Patents
Triazole sulphonyl propanedioic acid compounds, Preparation Method And The Use that alkoxyl group replaces Download PDFInfo
- Publication number
- CN104311498B CN104311498B CN201410583839.2A CN201410583839A CN104311498B CN 104311498 B CN104311498 B CN 104311498B CN 201410583839 A CN201410583839 A CN 201410583839A CN 104311498 B CN104311498 B CN 104311498B
- Authority
- CN
- China
- Prior art keywords
- compound
- present
- sulphonyl
- triazole
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 125000003545 alkoxy group Chemical group 0.000 title abstract description 5
- -1 Triazole sulphonyl propanedioic acid compounds Chemical class 0.000 title description 2
- 201000005569 Gout Diseases 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 10
- 201000001431 Hyperuricemia Diseases 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 42
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 claims description 6
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 claims description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 claims description 4
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 claims description 3
- 229960005215 dichloroacetic acid Drugs 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- BEPAFCGSDWSTEL-UHFFFAOYSA-N dimethyl malonate Chemical class COC(=O)CC(=O)OC BEPAFCGSDWSTEL-UHFFFAOYSA-N 0.000 claims description 2
- 235000010288 sodium nitrite Nutrition 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 9
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 9
- 229940116269 uric acid Drugs 0.000 abstract description 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract description 2
- 239000003112 inhibitor Substances 0.000 abstract description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 101000821903 Homo sapiens Solute carrier family 22 member 12 Proteins 0.000 description 10
- 102100021495 Solute carrier family 22 member 12 Human genes 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000003756 stirring Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- FGQFOYHRJSUHMR-UHFFFAOYSA-N lesinurad Chemical compound OC(=O)CSC1=NN=C(Br)N1C(C1=CC=CC=C11)=CC=C1C1CC1 FGQFOYHRJSUHMR-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 238000000967 suction filtration Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 229960003838 lesinurad Drugs 0.000 description 3
- ASUMVAPLXCRBMA-UHFFFAOYSA-N (3,5-dichloro-4-hydroxyphenyl)-(2,3-dihydro-1,4-benzoxazin-4-yl)methanone Chemical compound C1=C(Cl)C(O)=C(Cl)C=C1C(=O)N1C2=CC=CC=C2OCC1 ASUMVAPLXCRBMA-UHFFFAOYSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- 241001415342 Ardea Species 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229940083914 URAT1 inhibitor Drugs 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 2
- 229960002529 benzbromarone Drugs 0.000 description 2
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002000 scavenging effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010051779 Bone marrow toxicity Diseases 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010068701 Pegloticase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- CHQVQXZFZHACQQ-UHFFFAOYSA-M benzyl(triethyl)azanium;bromide Chemical compound [Br-].CC[N+](CC)(CC)CC1=CC=CC=C1 CHQVQXZFZHACQQ-UHFFFAOYSA-M 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 231100000366 bone marrow toxicity Toxicity 0.000 description 1
- NEEHYRZPVYRGPP-IYEMJOQQSA-L calcium gluconate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O NEEHYRZPVYRGPP-IYEMJOQQSA-L 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 229960005101 febuxostat Drugs 0.000 description 1
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical class [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229960001376 pegloticase Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- 229960003189 potassium gluconate Drugs 0.000 description 1
- 235000013926 potassium gluconate Nutrition 0.000 description 1
- ZVIWEYTXPYNLGB-UHFFFAOYSA-M potassium;4-[[2-[[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-1,2,4-triazol-3-yl]sulfanyl]acetyl]amino]-3-chlorobenzoate Chemical compound [K+].ClC1=CC(C(=O)[O-])=CC=C1NC(=O)CSC1=NN=C(Br)N1C(C1=CC=CC=C11)=CC=C1C1CC1 ZVIWEYTXPYNLGB-UHFFFAOYSA-M 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to the pharmaceutical field relevant to hyperuricemia and gout.Specifically, the present invention relates to uric acid transporter body 1 inhibitor of triazole sulphonyl propanedioic acid structure that a class replaces containing alkoxyl group, its preparation method and preparing the application in diabetes medicament containing their pharmaceutical composition and they.
wherein, R is selected from H, C
1-C
8alkyl, C
3-C
6cycloalkyl.
Description
Technical field
The present invention relates to the pharmaceutical field that treatment hyperuricemia is relevant with gout.Specifically, the present invention relates to uric acid transporter body 1 (uratetransporter1, the URAT1) inhibitor to the triazole sulphonyl propanedioic acid structure that hyperuricemia and the medicative class of gout replace containing alkoxyl group, preparation method, containing they pharmaceutical composition and in purposes pharmaceutically.
Background technology
Gout is a kind of chronic metabolic disease, and the pain being deposited on the positions such as joint with hyperuricemia and monosodium urate salt (MSU) and causing is for principal character, and major cause is purine metabolic disturbance and/or uric acid excretion disorder.According to estimates, current global patient with gout has more than 2,000 ten thousand.The medicine being used for the treatment of gout at present comprises for lenitive anti-inflammatory drug (as colchicine etc.), suppresses uricogenesis medicine (xanthine oxidase inhibitor being representative with allopurinol and Febuxostat), thick uric acid excretion medicine (the uric acid excretion medicine being representative with probenecid, sulfinpyrazone, benzbromarone and losartan) and uriKoxidase (with pegloticase for representative).There is the toxic side effect of different degree in these medicines, as benzbromarone has the danger causing explosive hepatitis, allopurinol has liver and the untoward reaction such as bone marrow toxicity and transformation reactions, etc.
Lesinurad (RDEA594) be a kind of developed by Ardea company can suppress uric acid transporter body (uratetransporter1 in kidney, URAT1) discharged the oral pharmaceutical of uric acid in blood by the approach of urine, be in III phase clinical stage at present.The antiviral RDEA806 that Lesinurad is researched and developed by Valeant company the earliest develops.The right of ownership of present Lesinurad is at present because Ardea company is belonged to AstraZeneca by purchasing.
The invention discloses the URAT1 inhibitor of the triazole sulphonyl propanedioic acid structure that a class alkoxyl group replaces, these compounds can be used for the medicine preparing treatment hyperuricemia and gout.
Summary of the invention
An object of the present invention is to provide one and there is excellent activity, there is a compounds of general formula I.
Another object of the present invention is to provide the method that preparation has the compound of general formula I.
Now in conjunction with object of the present invention, content of the present invention is specifically described.
The compound that the present invention has general formula (I) has following structural formula:
Wherein, R is selected from H, C
1-C
8alkyl, C
3-C
6cycloalkyl.
Preferred: R is selected from H, C
1-C
4alkyl, C
3-C
4cycloalkyl.
More preferably the compound of general formula (I) has following structure,
General formula of the present invention (I) compound is synthesized by following route:
Compound II per and alpha-brominated dimethyl malonate react in the presence of a base, obtain compound IV; Compound IV is obtained by reacting compound V with Sodium Nitrite and dichloro acetic acid in bromofom; Compound V is hydrolyzed in the basic conditions and obtains compound VI; Compound VI and 2 equivalents and above oxidizingly obtain Compound I.
Compound of Formula I of the present invention has the restraining effect of URAT1, can be used as the medicine of effective constituent for the preparation of hyperuricemia and gout.The activity of compound of Formula I of the present invention is verified by receptor binding assays.
Compound of Formula I of the present invention is effective in quite wide dosage range.The dosage that such as every day takes, within the scope of 1mg-500mg/ people, is divided into once or administration for several times.The actual dosage taking compound of Formula I of the present invention can be decided according to relevant situation by doctor.
Embodiment
Below in conjunction with embodiment, the present invention is further illustrated.It should be noted that, following embodiment be only for illustration of, and not for limiting the present invention.The various changes that those skilled in the art's training centre according to the present invention is made all should within the protection domain required by the application's claim.
the synthesis of embodiment 1 Compound I-1
A. the synthesis of compound IV-1
5.44g (20mmol) Compound II per-1 and 4.22g (20mmol) compound III are dissolved in the DMF of 100mL drying, and stirred at ambient temperature adds 8.29g (60mmol) solid K
2cO
3, then reaction mixture at room temperature stirs, until TLC follows the tracks of find that reaction completes (within general 12h).Reaction mixture pours in 400mL frozen water, stirs, and uses the CH of 100mL × 3
2cl
2extraction, merges extraction phase, uses the salt water washing of 100mL5%, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound IV-1, white-yellowish solid, ESI-MS, m/z=425 ([M+Na]
+).
B. the synthesis of compound V-1
4.82g (12mmol) compound IV-1 is dissolved in 30mL bromofom, stirred at ambient temperature, adds 3.45g (50mmol) NaNO
2with 3.00g benzyl triethyl ammonium bromide, then add 6.45g (50mmol) dichloro acetic acid.Gained mixture at room temperature stirs, until TLC follows the tracks of find that reaction completes (within general 12h).Reaction mixture pours in 300mL frozen water, stirs, and uses the CH of 100mL × 3
2cl
2extraction, merges extraction phase, uses the Na of 100mL2% successively
2s
2o
3the salt water washing of solution and 100mL5%, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound V-1, white solid, ESI-MS, m/z=489 ([M+Na]
+).
C. the synthesis of compound VI-1
3.72g (8mmol) compound V-1 is dissolved in 30mL methyl alcohol, and stirred at ambient temperature adds the LiOH solution of 3mL10%, gained mixture stirred at ambient temperature, until TLC follows the tracks of find that reaction completes (within general 3h).Reaction mixture pours in 200mL frozen water, stirs, and uses concentrated hydrochloric acid to regulate the CH of pH=2-3,100mL × 3
2cl
2extraction, merges extraction phase, uses the salt water washing of 100mL5%, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains compound VI-1, white solid, ESI-MS, m/z=438,436 ([M-H]-).
D.
the synthesis of Compound I-1
2.62g (6mmol) compound VI-1 is dissolved in 10mLCH
2cl
2in, stir, add 2.41g (14mmol) metachloroperbenzoic acid (mCPBA), stirred at ambient temperature 5h hour.Reaction mixture pours in 200mL frozen water, stirs, the CH of 100mL × 3
2cl
2extraction, merges extraction phase, uses 100mL2%Na successively
2s
2o
3the saturated NaHCO of solution, 100mL
3with the salt water washing of 100mL5%, anhydrous sodium sulfate drying.Suction filtration removing siccative, filtrate is evaporate to dryness on a rotary evaporator, and the resistates obtained uses column chromatography purification, obtains Compound I-1, white solid, ESI-MS, m/z=470,468 ([M-H]
-).
embodiment 2-6
With reference to embodiment 1 operation steps, synthesize compound listed in Table.
embodiment 7
Compound of the present invention and related compound measure (in US2014/0005136 embodiment 12) to the similar method that the IC50 value that URAT1 suppresses is recorded according to document.
Build the cell strain of stably express humanization URAT1 transporter: be subcloned into the plasmid pCMV6/neo (Origene) of eukaryotic expression from plasmid pCMV6-XL-5 (Origene) by humanization URAT1 gene (SLC22A112).Gene sequencing confirms humanization URAT1 consistent with the information recorded in gene pool (NM_144585.2).HEK293 human embryonic kidney cell (ATCC#CRL-1573) in EMEM tissue culture medium at the CO of 5%
2cultivate with in the air atmosphere of 95%.L2000 type transfection agents (Invitrogene) is used to be transfected on HEK293 cell by pCMV6/Neo/URAT1.After 24 hours, transfected cell being assigned to diameter is in the tissue culture dishes of 10cm, continued growth one day, then substratum is replaced by the fresh substratum containing 0.5mg/mLG418 (Gibco).After 8 days, select and collect resistance bacterium colony, and right with its test
14the transport activity of the uric acid of C-mark.By HEK293/URAT1 cell with 75, the density in 000/ hole is planted on 96 orifice plates that cover in poly-D-Lys.
These cells grow overnight at 37 DEG C in incubator, then under cool to room temperature, nutrient solution wherein uses the scavenging solution washing in 250 μ L/ holes once (10mMHEPES of 125mM Sunmorl N 60S, pH=7.3).Testing compound or blank be added to containing 40 μMs
14c-marks in the damping fluid of uric acid (54mCi/mmol), described damping fluid contains 125mM Sunmorl N 60S, 4.8mM Potassium Gluconate, 1.2mM potassium primary phosphate, 1.2mM magnesium sulfate, 1.3mM calglucon, 5.6mM glucose, 25mMHEPES, final pH=7.3.96 orifice plates at room temperature cultivate 10 minutes, then respectively clean three times with the above-mentioned scavenging solution in 50 μ L/ holes and 250 μ L/ holes successively.96 orifice plates add Microscint20 type liquid and dodges agent, plank is overnight incubation at 45 DEG C, then reading on TopCountPlateReader, and calculates IC accordingly
50.
Shown in the following list of result:
Part of compounds of the present invention is to the IC of URAT1
50value
| Compound | IC 50(hURAT1,nM) |
| Lesinurad | 22.4 |
| I-1 | 14.9 |
| I-2 | 32.8 |
| I-3 | 18.1 |
| I-4 | 21.5 |
| I-5 | 24.2 |
| I-6 | 25.7 |
Above-mentioned IC
50measurement result show, the compounds of this invention is strong URAT1 inhibitor, can be used for preparing treatment hyperuricemia and the medicine of gout.
Claims (3)
1. following compounds,
2. synthesize the method for compound described in claim 1:
Compound II per and alpha-brominated dimethyl malonate react in the presence of a base, obtain compound IV; Compound IV is obtained by reacting compound V with Sodium Nitrite and dichloro acetic acid in bromofom; Compound V is hydrolyzed in the basic conditions and obtains compound VI; Compound VI and 2 equivalents and above oxidizingly obtain Compound I; Wherein, R is selected from methyl, ethyl.
3. the purposes of compound described in claim 1 in preparation treatment hyperuricemia and gout medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410583839.2A CN104311498B (en) | 2014-10-27 | 2014-10-27 | Triazole sulphonyl propanedioic acid compounds, Preparation Method And The Use that alkoxyl group replaces |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410583839.2A CN104311498B (en) | 2014-10-27 | 2014-10-27 | Triazole sulphonyl propanedioic acid compounds, Preparation Method And The Use that alkoxyl group replaces |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104311498A CN104311498A (en) | 2015-01-28 |
| CN104311498B true CN104311498B (en) | 2016-04-06 |
Family
ID=52366841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410583839.2A Expired - Fee Related CN104311498B (en) | 2014-10-27 | 2014-10-27 | Triazole sulphonyl propanedioic acid compounds, Preparation Method And The Use that alkoxyl group replaces |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104311498B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101083987A (en) * | 2004-08-25 | 2007-12-05 | 阿迪亚生命科学公司 | S-tryazolyl alpha,-mercaptoacetanliides as inhibitors of HIV reverse transcriptase |
| CN102186832A (en) * | 2008-09-04 | 2011-09-14 | 亚德生化公司 | Compounds, compositions and methods of using same for modulating uric acid levels |
| WO2014008295A1 (en) * | 2012-07-03 | 2014-01-09 | Ardea Biosciences, Inc. | Manufacture of 2- (5- bromo-4 (-cyclopropylnaphthalen-1-yl) -4h-1,2,4-triazol-3-ylthio) acetic acid |
-
2014
- 2014-10-27 CN CN201410583839.2A patent/CN104311498B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101083987A (en) * | 2004-08-25 | 2007-12-05 | 阿迪亚生命科学公司 | S-tryazolyl alpha,-mercaptoacetanliides as inhibitors of HIV reverse transcriptase |
| CN102186832A (en) * | 2008-09-04 | 2011-09-14 | 亚德生化公司 | Compounds, compositions and methods of using same for modulating uric acid levels |
| WO2014008295A1 (en) * | 2012-07-03 | 2014-01-09 | Ardea Biosciences, Inc. | Manufacture of 2- (5- bromo-4 (-cyclopropylnaphthalen-1-yl) -4h-1,2,4-triazol-3-ylthio) acetic acid |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104311498A (en) | 2015-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104311442B (en) | The succinamide derivative of halo naphthalene nucleus, Preparation Method And The Use | |
| CN104311498B (en) | Triazole sulphonyl propanedioic acid compounds, Preparation Method And The Use that alkoxyl group replaces | |
| CN104292123B (en) | The succinamide derivative of phenyl naphthalene nucleus, Preparation Method And The Use | |
| CN104341362A (en) | Triazolesulfonylmalonic acid compounds as well as preparation method and application thereof | |
| CN104341364A (en) | Triazole malonic acid compounds as well as preparation method and application thereof | |
| CN104370841A (en) | Triazolesulfinylmalonic acid compounds as well as preparation method and application thereof | |
| CN104262277A (en) | Nitro containing and halogen benzene substituted 1H-tetrazole-1-acetic acid structure, and preparation method and use thereof | |
| CN104292178B (en) | Containing tetrazoleacetic acid compounds, Preparation Method And The Use | |
| CN104326999B (en) | Alkoxy-substituted triazole sulfinyl malonate type compound, and preparation method and application thereof | |
| CN104370842B (en) | The triazole sulphonyl malonic acid compounds of phenyl replacement, Preparation Method And The Use | |
| CN104292124B (en) | Naphthalene nucleus succinamide derivative, Preparation Method And The Use that nitrophenyl replaces | |
| CN104311445B (en) | Naphthalene-ring containing succinamide derivative, Preparation Method And The Use | |
| CN104311443B (en) | The naphthalene-ring containing succinamide derivative of one class, Preparation Method And The Use | |
| CN104193644B (en) | The succinamide derivative of methoxy naphthalene nucleus, Preparation Method And The Use | |
| CN104311452B (en) | The succinamide derivative of itrile group naphthalene nucleus, Preparation Method And The Use | |
| CN104311441B (en) | Succinamide derivative, the Preparation Method And The Use of one class chloro naphthalene nucleus | |
| CN104356078A (en) | Halogenated triazole sulfuryl malonic acid compound, as well as preparation method and application thereof | |
| CN104326997A (en) | Alkoxy-substituted triazole malonate type compound, and preparation method and application thereof | |
| CN104370843B (en) | Halo triazole sulfenyl malonic acid compounds, Preparation Method And The Use | |
| CN104327000A (en) | Phenyl-substituted triazole sulfinyl malonate type compound, and preparation method and application thereof | |
| CN104341365A (en) | Halogenated triazole malonic acid compounds as well as preparation method and application thereof | |
| CN104230833B (en) | The tetrazoleacetic acid compounds of nitrile group-containing, Preparation Method And The Use | |
| CN104326998A (en) | Phenyl-substituted triazole malonate type compound, and preparation method and application thereof | |
| CN104311444B (en) | Nitro replaces succinamide derivative, the Preparation Method And The Use of naphthalene nucleus | |
| CN104341363A (en) | Nitro-substituted triazolesulfonylmalonic acid compounds as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20181213 Address after: 225300 Pearl River Road, Yongan Town, Taizhou, Jiangsu Province, 108 Patentee after: Wang Yajun Address before: 528000 floor 5, Pu Lan Road, Chancheng District, Foshan, Guangdong. Patentee before: Zhang Yuanqiang |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190925 Address after: 325000 Liulong Bridge Road, Liulong Village, Qiaoxia Town, Yongjia County, Wenzhou City, Zhejiang Province Patentee after: Li De Song Address before: 225300 No. 108 Mingzhu Avenue, Yonganzhou Town, Gaogang District, Taizhou City, Jiangsu Province Patentee before: Wang Ya Jun |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160406 Termination date: 20201027 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |